Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines

BACKGROUND: Immune checkpoint inhibitors (ICIs) have led to a paradigm change in the management of metastatic renal cell carcinoma (mRCC). Prospective trials have focused on ICI treatment in the first or second line. The aim of this analysis is to evaluate the benefit of ICI across different treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Resch, I., Bruchbacher, A., Franke, J., Fajkovic, H., Remzi, M., Shariat, S.F., Schmidinger, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261552/
https://www.ncbi.nlm.nih.gov/pubmed/34217917
http://dx.doi.org/10.1016/j.esmoop.2021.100122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261552/
https://www.ncbi.nlm.nih.gov/pubmed/34217917
http://dx.doi.org/10.1016/j.esmoop.2021.100122

Ejemplares similares